In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD
While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s not approved in Australia—and comes with notable side effects.
Instead, Australia is the only country in the world to approve a regulated androgen hormone treatment specifically for postmenopausal women with HSDD. This topical therapy restores androgen levels to those typical of premenopausal women and is backed by decades of Australian-led research.
This marks a major step forward in addressing gender equity in sexual health care.
Latest News
World Menopause Day is held every year on 18 October.
World Menopause Day Founded by the International Menopause Society (IMS) in 2009, it is a global awareness day that shines a spotlight on the… Continue Reading →
How Often Is “Normal”? Rethinking Sexual Frequency and Satisfaction
Sexual satisfaction isn’t about frequency—it’s about connection, comfort, and wellbeing. There’s no “right” amount of sex—but many women feel pressure to meet unrealistic expectations…. Continue Reading →
Free CPD Education: Diagnose & Manage HSDD
Empower Your Practice: Address HSDD with Confidence Hypoactive Sexual Desire Disorder (HSDD) is a common yet often overlooked concern in general practice—especially among postmenopausal… Continue Reading →